JP2022169589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022169589A5 JP2022169589A5 JP2022124782A JP2022124782A JP2022169589A5 JP 2022169589 A5 JP2022169589 A5 JP 2022169589A5 JP 2022124782 A JP2022124782 A JP 2022124782A JP 2022124782 A JP2022124782 A JP 2022124782A JP 2022169589 A5 JP2022169589 A5 JP 2022169589A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- seq
- pharmaceutical composition
- amino acids
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 14
- 102000037865 fusion proteins Human genes 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000025171 antigen binding proteins Human genes 0.000 claims 3
- 108091000831 antigen binding proteins Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- -1 glidant Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16188871 | 2016-09-15 | ||
| EP16188871.4 | 2016-09-15 | ||
| JP2019514232A JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
| PCT/EP2017/073328 WO2018050848A1 (en) | 2016-09-15 | 2017-09-15 | Antigen binding protein against her3 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514232A Division JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022169589A JP2022169589A (ja) | 2022-11-09 |
| JP2022169589A5 true JP2022169589A5 (https=) | 2023-01-17 |
| JP7638531B2 JP7638531B2 (ja) | 2025-03-04 |
Family
ID=57017956
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514232A Active JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
| JP2022124782A Active JP7638531B2 (ja) | 2016-09-15 | 2022-08-04 | Ｈｅｒ３に対する抗原結合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514232A Active JP7203426B2 (ja) | 2016-09-15 | 2017-09-15 | Ｈｅｒ３に対する抗原結合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11008402B2 (https=) |
| EP (1) | EP3512886B1 (https=) |
| JP (2) | JP7203426B2 (https=) |
| KR (1) | KR102469700B1 (https=) |
| CN (1) | CN110167968B (https=) |
| AU (1) | AU2017327769B2 (https=) |
| BR (1) | BR112019005001A2 (https=) |
| CA (1) | CA3033694C (https=) |
| DK (1) | DK3512886T3 (https=) |
| ES (1) | ES3037145T3 (https=) |
| MX (1) | MX2019002664A (https=) |
| WO (1) | WO2018050848A1 (https=) |
| ZA (1) | ZA201901379B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019179627A1 (en) * | 2018-03-22 | 2019-09-26 | Universität Stuttgart | Multivalent binding molecules |
| PE20210111A1 (es) | 2018-04-11 | 2021-01-19 | Salubris Biotherapeutics Inc | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022550316A (ja) * | 2019-09-25 | 2022-12-01 | ウニヴェルズィテート シュトゥットガルト | 修飾ｅｈｄ２ドメインを含む結合モジュール |
| US20220396635A1 (en) * | 2019-09-25 | 2022-12-15 | Universität Stuttgart | Trivalent binding molecules |
| WO2022061256A2 (en) * | 2020-09-21 | 2022-03-24 | Systimmune, Inc. | Egfr binding complex and method of making and using thereof |
| CN116133694B (zh) * | 2020-10-14 | 2026-03-06 | 苏州盛迪亚生物医药有限公司 | 抗her3抗体和抗her3抗体药物偶联物及其医药用途 |
| AU2023228226A1 (en) * | 2022-03-03 | 2024-10-03 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Her3 binding protein and use thereof |
| CN115057946B (zh) * | 2022-06-30 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | 干扰素在制备抗广谱流感病毒和冠状病毒药物中的应用 |
| KR20250161618A (ko) * | 2023-03-17 | 2025-11-17 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-her3 및 항-met 항체 및 이의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| CA2025907A1 (en) | 1989-09-21 | 1991-03-22 | Franklin D. Collins | Method of transporting compositions across the blood brain barrier |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP2400021B1 (en) * | 2002-03-26 | 2016-11-30 | Zensun (Shanghai) Science & Technology, Co., Ltd. | ErbB3 based methods and compositions for treating neoplasms |
| MX358013B (es) | 2009-11-13 | 2018-08-01 | Amgen Inc | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. |
| WO2013016714A1 (en) * | 2011-07-28 | 2013-01-31 | Sea Lane Biotechnologies | Sur-binding proteins against erbb3 |
| RU2014126098A (ru) * | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
| EA201491120A1 (ru) * | 2011-12-05 | 2015-07-30 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3 |
| EP2912066A4 (en) | 2012-10-25 | 2016-10-12 | Sorrento Therapeutics Inc | ANTIGENBINDING PROTEINS FOR BINDING ERBB3 |
-
2017
- 2017-09-15 CN CN201780057182.8A patent/CN110167968B/zh active Active
- 2017-09-15 WO PCT/EP2017/073328 patent/WO2018050848A1/en not_active Ceased
- 2017-09-15 EP EP17768777.9A patent/EP3512886B1/en active Active
- 2017-09-15 MX MX2019002664A patent/MX2019002664A/es unknown
- 2017-09-15 DK DK17768777.9T patent/DK3512886T3/da active
- 2017-09-15 AU AU2017327769A patent/AU2017327769B2/en active Active
- 2017-09-15 CA CA3033694A patent/CA3033694C/en active Active
- 2017-09-15 JP JP2019514232A patent/JP7203426B2/ja active Active
- 2017-09-15 ES ES17768777T patent/ES3037145T3/es active Active
- 2017-09-15 KR KR1020197009096A patent/KR102469700B1/ko active Active
- 2017-09-15 BR BR112019005001-9A patent/BR112019005001A2/pt active Search and Examination
- 2017-09-15 US US16/326,864 patent/US11008402B2/en active Active
-
2019
- 2019-03-05 ZA ZA2019/01379A patent/ZA201901379B/en unknown
-
2022
- 2022-08-04 JP JP2022124782A patent/JP7638531B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022169589A5 (https=) | ||
| JP2025111463A5 (https=) | ||
| RU2017139490A (ru) | Конъюгаты лекарственных средств, содержащие антитела против клаудина 18.2 | |
| JP2022079549A5 (https=) | ||
| CN108473563B (zh) | 改进的tnf结合剂 | |
| JP2021531732A5 (https=) | ||
| CA3173919A1 (en) | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer | |
| JP2025038088A5 (https=) | ||
| RU2018107693A (ru) | Комбинированные виды лечения и их варианты применения и способы | |
| US20230071019A1 (en) | Compositions and methods for reducing off-target toxicity of antibody drug conjugates | |
| JP2021512613A5 (https=) | ||
| JP2021506817A5 (https=) | ||
| WO2024131949A1 (zh) | Anti-cMet抗体、抗体药物偶联物及其制备方法和用途 | |
| CN117645608A (zh) | 抗体药物偶联物及其应用 | |
| CN114106088A (zh) | 基于溴甲基吡嗪的药物偶联物及adc | |
| JPWO2022147532A5 (https=) | ||
| JPWO2019204272A5 (https=) | ||
| US20260035463A1 (en) | Multispecific antibody and use thereof | |
| JPWO2022256559A5 (https=) | ||
| CN103417965B (zh) | 一种含有抗vegf抗体的药物组合物 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JPWO2020074724A5 (https=) | ||
| JPWO2020218951A5 (https=) | ||
| WO2022127066A1 (zh) | 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途 | |
| JPWO2021091359A5 (https=) |